Cargando…
Bamlanivimab: Transfusion-related acute lung injury following off label use: case report
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8532465/ http://dx.doi.org/10.1007/s40278-021-04087-2 |
Ejemplares similares
-
Bamlanivimab: Gene mutation in COVID-19 infection and off label use: case report
Publicado: (2022) -
Bamlanivimab: Diffuse C4d staining of peritubular capillaries following off-label use: case report
Publicado: (2022) -
Bamlanivimab/immunosuppressants: Headache/fatigue following off-label treatment and Coronavirus disease-2019: 18 case reports
Publicado: (2022) -
Bamlanivimab/casirivimab/imdevimab: Burning, eye pain and lack of efficacy following off-label use: 8 case reports
Publicado: (2022) -
Convalescent-anti-SARS-CoV-2-plasma: Transfusion-related acute lung injury following off-label use: case report
Publicado: (2021)